{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:14:12Z","timestamp":1767651252997},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,8,27]],"date-time":"2014-08-27T00:00:00Z","timestamp":1409097600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s12185-014-1631-x","type":"journal-article","created":{"date-parts":[[2014,8,26]],"date-time":"2014-08-26T13:09:40Z","timestamp":1409058580000},"page":"353-360","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Phase III, single-arm study investigating the efficacy, safety, and tolerability of anagrelide as a second-line treatment in high-risk Japanese patients with essential thrombocythemia"],"prefix":"10.1007","volume":"100","author":[{"given":"Yuzuru","family":"Kanakura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Miyakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Wilde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinrich","family":"Achenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,8,27]]},"reference":[{"key":"1631_CR1","volume-title":"WHO classification of tumours of haemopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haemopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008.","edition":"4"},{"key":"1631_CR2","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","volume":"296","author":"T Barbui","year":"2011","unstructured":"Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;296:761\u201370.","journal-title":"J Clin Oncol"},{"key":"1631_CR3","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2141.2010.08122.x","volume":"1493","author":"CN Harrison","year":"2010","unstructured":"Harrison CN, Bareford D, Butt N, Campbell P, Conneally E, Drummond M, et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol. 2010;1493:352\u201375.","journal-title":"Br J Haematol"},{"key":"1631_CR4","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1532\/IJH97.06009","volume":"835","author":"K Dan","year":"2006","unstructured":"Dan K, Yamada T, Kimura Y, Usui N, Okamoto S, Sugihara T, et al. Clinical features of polycythemia vera and essential thrombocythemia in Japan: retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group. Int J Hematol. 2006;835:443\u20139.","journal-title":"Int J Hematol"},{"key":"1631_CR5","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","volume":"2929","author":"JJ Kiladjian","year":"2011","unstructured":"Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol. 2011;2929:3907\u201313.","journal-title":"J Clin Oncol"},{"key":"1631_CR6","unstructured":"European Medicines Agency. Xagrid summary of product characteristics, Shire Pharmaceuticals Ltd. Available from http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000480\/WC500056557.pdf 2014 (Accessed on 5 Feb 2014)."},{"key":"1631_CR7","unstructured":"Shire PLC. AGRYLIN (anagrelide hydrochloride). Available from www.shire.com\/shireplc\/en\/products\/other\/AGRYLIN 2012 (Accessed on 28 Nov 2013)."},{"key":"1631_CR8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.leu.2404473","volume":"212","author":"G Barosi","year":"2007","unstructured":"Barosi G, Besses C, Birgegard G, Briere J, Cervantes F, Finazzi G, et al. A unified definition of clinical resistance\/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia. 2007;212:277\u201380.","journal-title":"Leukemia"},{"key":"1631_CR9","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s12185-013-1265-4","volume":"973","author":"S Okamoto","year":"2013","unstructured":"Okamoto S, Miyakawa Y, Smith J, Hodgson I, Abhyankar B, Troy S, et al. Open-label, dose-titration and continuation study to assess efficacy, safety, and pharmacokinetics of anagrelide in treatment-naive Japanese patients with essential thrombocythemia. Int J Hematol. 2013;973:360\u20138.","journal-title":"Int J Hematol"},{"key":"1631_CR10","unstructured":"US Food and Drug Administration (FDA). Summary of product characteristics. Available from http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2004\/20333s010lbl.pdf 2012 (Accessed on 16 Aug 2012)."},{"key":"1631_CR11","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","volume":"12110","author":"H Gisslinger","year":"2013","unstructured":"Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, et al. Anagrelide compared to hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013;12110:1720\u20138.","journal-title":"Blood"},{"key":"1631_CR12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","volume":"3531","author":"CN Harrison","year":"2005","unstructured":"Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;3531:33\u201345.","journal-title":"N Engl J Med"},{"key":"1631_CR13","unstructured":"Nam S, Abhyankar B, Choi Y, Jung J. Safety of anagrelide in clinical practice: a multi-centre post-marketing surveillance study in Korea. Abstract at the 74th Annual Meeting of the Japanese Society of Hematology (JSH), Kyoto, Japan, 19\u201321 October 2012."},{"key":"1631_CR14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1539\/sangyoeisei.E9007","volume":"521","author":"T Shimomura","year":"2010","unstructured":"Shimomura T. Wakabayashi I [Regional differences in prevalence of anemia found by periodic health checkups at workplaces in Japan]. Sangyo Eiseigaku Zasshi. 2010;521:21\u20137.","journal-title":"Sangyo Eiseigaku Zasshi"},{"key":"1631_CR15","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1586\/era.11.10","volume":"113","author":"JL Spivak","year":"2011","unstructured":"Spivak JL, Hasselbalch H. Hydroxycarbamide: a user\u2019s guide for chronic myeloproliferative disorders. Expert Rev Anticancer Ther. 2011;113:403\u201314.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1631_CR16","doi-asserted-by":"crossref","unstructured":"Gugliotta L, Besses C, Griesshammer M, Harrison C, Kiladjian JJ, Coll R, et al. Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid (R): efficacy and long-term safety study. Haematologica. 2014;99:679\u201387.","DOI":"10.3324\/haematol.2012.083097"},{"key":"1631_CR17","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.leukres.2012.11.004","volume":"372","author":"C Besses","year":"2013","unstructured":"Besses C, Kiladjian JJ, Griesshammer M, Gugliotta L, Harrison C, Coll R, et al. Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study. Leuk Res. 2013;372:162\u20138.","journal-title":"Leuk Res"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-014-1631-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-014-1631-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-014-1631-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T05:11:20Z","timestamp":1559452280000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-014-1631-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,27]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["1631"],"URL":"https:\/\/doi.org\/10.1007\/s12185-014-1631-x","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,27]]}}}